P
Puyuan Xing
Researcher at Peking Union Medical College
Publications - 116
Citations - 878
Puyuan Xing is an academic researcher from Peking Union Medical College. The author has contributed to research in topics: Medicine & Lung cancer. The author has an hindex of 11, co-authored 64 publications receiving 446 citations.
Papers
More filters
Journal ArticleDOI
Phase I Study and Biomarker Analysis of Pyrotinib, a Novel Irreversible Pan-ErbB Receptor Tyrosine Kinase Inhibitor, in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer.
Fei Ma,Qiao Li,Shanshan Chen,Wenjie Zhu,Ying Fan,Jiayu Wang,Yang Luo,Puyuan Xing,Bo Lan,Meiying Li,Zongbi Yi,Ruigang Cai,Peng Yuan,Pin Zhang,Qing Li,Binghe Xu +15 more
TL;DR: Continuous once-per-day pyrotinib was well tolerated and demonstrated promising antitumor activity in HER2-positive patients with metastatic breast cancer, and preliminary results suggest that PIK3CA and TP53 mutations in circulating tumor DNA rather than in archival tumor tissues may predict the efficacy of pyrot inib.
Journal ArticleDOI
Incidence rates of immune-related adverse events and their correlation with response in advanced solid tumours treated with NIVO or NIVO+IPI: a systematic review and meta-analysis.
Puyuan Xing,Fan Zhang,Guoqiang Wang,Yu Xu,Chengcheng Li,S. Wang,Yiying Guo,Shangli Cai,Yan Wang,Junling Li +9 more
TL;DR: This meta-analysis summarizes the incidence rates of irAEs in patients with advanced solid tumours treated with NIVO or NivO+IPI, and uncovers their correlations with ORR across multiple neoplasms.
Journal ArticleDOI
A phase II study of biweekly paclitaxel and cisplatin chemotherapy for recurrent or metastatic esophageal squamous cell carcinoma: ERCC1 expression predicts response to chemotherapy
Jing Huang,Yi Zhou,Hongtu Zhang,Tao Qu,Yousheng Mao,Hongxia Zhu,Lanping Quan,Puyuan Xing,Jinwan Wang,Jie He,Ningzhi Xu,Yan Sun +11 more
TL;DR: It is indicated that the expression of ERCC1 evaluated by immunohistochemistry is a promising predictive marker for response in patients with metastatic ESCC receiving cisplatin–paclitaxel regimen.
Journal ArticleDOI
Acquired resistance to osimertinib in patients with non-small-cell lung cancer: mechanisms and clinical outcomes
Yuxin Mu,Xuezhi Hao,Puyuan Xing,Xingsheng Hu,Yan Wang,Teng Li,Jinyao Zhang,Ziyi Xu,Junling Li +8 more
TL;DR: Heterogeneous mechanisms of resistance to osimertinib in advanced NSCLC patients and their association with clinical outcomes are revealed.
Journal ArticleDOI
Distribution of ALK Fusion Variants and Correlation with Clinical Outcomes in Chinese Patients with Non-Small Cell Lung Cancer Treated with Crizotinib
Yudong Su,Xiang Long,Yang Song,Peng Chen,Shanqing Li,Huaxia Yang,Pancheng Wu,Yanyu Wang,Zhongxing Bing,Zhili Cao,Lei Cao,Yijun Wu,Zhe Zhang,Jing Liu,Bing Li,Jianxing Xiang,Ke Ma,Tengfei Zhang,Lu Zhang,Xinru Mao,Hao Liu,Puyuan Xing,Naixin Liang +22 more
TL;DR: This study illustrates the patterns of ALK fusion variants present in Chinese NSCLC patients and might help explain heterogeneous clinical outcomes to crizotinib treatment according to different ALK fused variants.